| Quarterly Financials | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 10 | 34 | 88 | 76 | 296 | 338 | 399 | 429 | 333 | 379 |
| Expenses | 80 | 105 | 173 | 76 | 233 | 263 | 351 | 244 | 242 | 269 |
| EBITDA | -70 | -71 | -85 | -0 | 64 | 76 | 48 | 185 | 91 | 110 |
| Operating Profit % | -800 % | -210 % | -207 % | -4 % | 20 % | 21 % | 11 % | 43 % | 26 % | 28 % |
| Depreciation | 19 | 18 | 20 | 20 | 68 | 68 | 69 | 69 | 68 | 70 |
| Interest | 18 | 25 | 26 | 21 | 42 | 45 | 46 | 33 | 28 | 34 |
| Profit Before Tax | -107 | -114 | -130 | -40 | -47 | -38 | -67 | 83 | -4 | 6 |
| Tax | 0 | 0 | 0 | 0 | -41 | 5 | 2 | -16 | -4 | -5 |
| Net Profit | -107 | -114 | -130 | -40 | -6 | -42 | -69 | 99 | -0 | 11 |
| EPS in ₹ | 0.00 | -27.37 | -31.32 | -9.67 | -0.51 | -10.13 | -6.31 | 8.61 | -0.02 | 0.92 |
Onesource Specialty Pharma
Onesource Specialty Pharma
1,532.20
-62.20
(-3.90%)
Market Cap
₹17,547.55 Cr
PE Ratio
479.56
Volume
4,83,483.00
Day High - Low
₹1,635.80 - ₹1,494.70
52W High-Low
₹2,248.00 - ₹1,209.95
Key Fundamentals
Market Cap
17,547.55 Cr
EPS
-1.63
PB Ratio
3.25
Book Value
515.40
EBITDA
484.00
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals ROE Growth %
-
Debt to Equity
0.21
Analyst Rating and Forecast
- By Refinitiv from4 analysts
Actual
Company News
View All News
OneSource Specialty Pharma Reports Strong Q2 Performance Despite GLP-1 Launch Uncertainties
10 days ago
10 days agoOneSource Specialty Pharma delivered 12% revenue growth to INR 3,758 million and 37% EBITDA growth to INR 1,065 million in Q2 FY26, with margins expanding 506 basis points to 28%. The company faces near-term revenue recognition uncertainty due to regulatory approval delays for GLP-1 customers including potential Canada launch delays, while maintaining confidence in FY28 guidance of INR 500 million revenue including proposed acquisitions.
OneSource Specialty Pharma Reports 12% Revenue Growth in Q2FY26, Raises FY28 Outlook to $500MNov 12, 2025
Nov 12, 2025OneSource Specialty Pharma delivered quarterly results showing revenue of $43.1 million, representing 12% year-over-year growth driven by MSA executions and IP-led base business sales. EBITDA reached $12.2 million with a 28% margin, marking 506 basis points improvement year-over-year. The company moved from loss to profit with adjusted PAT of $4.3 million. Performance was supported by signing 9 new MSAs and licensing agreements across different platforms. The company is accelerating DDC capacity additions to support upcoming customer launches and has onboarded 2 new device platforms, bringing total device platforms to 11. OneSource announced proposed acquisitions of a multi-dose fill-finish site in Europe and an integrated carbapenem facility in India. Based on these developments, the company raised its FY28 revenue outlook to $500 million with 40% EBITDA margins. The biologics funnel increased 4x versus FY25 driven by strengthened sales teams and industry tailwinds. Capacity expansion is progressing with cartridge capacity planned to increase from 40 million to 220 million units.
OneSource Specialty Pharma Limited reported quarterly results for the period ended September 30, 2025. The company's consolidated revenue increased to Rs. 3,787.63 million compared to Rs. 3,272.70 million in the previous quarter. However, the company posted a consolidated net loss of Rs. 104.85 million for the quarter, compared to a profit of Rs. 47.02 million in the previous quarter. For the six-month period, consolidated revenue reached Rs. 7,060.33 million versus Rs. 6,263.37 million in the corresponding period last year, while net loss widened to Rs. 72.80 million from Rs. 179.70 million loss in the previous year. The company operates primarily in the CDMO (Contract Development and Manufacturing Organization) segment for pharmaceutical products. The results include exceptional items related to business combination, listing, and post-merger integration expenses. The company is involved in ongoing litigation with Prestige Biopharma Limited regarding a USD 136.32 million claim related to Sputnik vaccine manufacturing, which is currently pending before the Singapore International Arbitration Centre.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,831.60 | #1 4,39,462.19 | 40.68 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 79.43 | |
6,477.00 | 1,71,944.00 | 69.05 | 9,712.00 | 18.67 | 2,191 | 35.10 | 49.62 | |
3,720.60 | 1,25,922.01 | 58.80 | 11,539.40 | 6.99 | 1,911 | 30.46 | 53.11 | |
1,531.30 | 1,23,691.38 | 22.73 | 28,409.50 | 7.12 | 5,291 | 3.71 | 50.63 | |
1,258.80 | 1,05,061.18 | #1 18.15 | 33,741.20 | 16.73 | 5,725 | -0.38 | 57.24 | |
2,082.20 | 95,105.43 | 21.34 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 65.07 | |
942.50 | 94,837.55 | 18.56 | 23,511.00 | 18.55 | 4,615 | 34.60 | 44.36 | |
2,251.00 | 92,911.94 | 52.05 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 38.76 | |
1,226.70 | 71,246.94 | 20.70 | 32,345.60 | 9.43 | 3,484 | 3.81 | 63.81 | |
5,685.00 | 67,972.70 | 28.29 | 13,458.30 | 3.70 | 2,216 | 10.98 | 53.82 |
Growth Rate
Revenue Growth
730.38 %
Net Income Growth
-95.27 %
Cash Flow Change
36.71 %
ROE
-99.69 %
ROCE
-103.78 %
EBITDA Margin (Avg.)
-169.39 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 1,258 | 2,442 | 2,009 | 1,309 | 7,550 |
| Fixed Assets | 633 | 1,231 | 1,361 | 863 | 6,118 |
| Current Assets | 99 | 511 | 228 | 176 | 1,086 |
| Capital Work in Progress | 431 | 490 | 335 | 188 | 218 |
| Investments | 0 | 0 | 5 | 20 | 16 |
| Other Assets | 195 | 722 | 309 | 238 | 1,199 |
| Total Liabilities | 1,258 | 2,442 | 2,009 | 1,309 | 7,550 |
| Current Liabilities | 161 | 809 | 865 | 631 | 1,114 |
| Non Current Liabilities | 321 | 621 | 358 | 282 | 556 |
| Total Equity | 776 | 1,013 | 786 | 396 | 5,881 |
| Reserve & Surplus | 775 | 1,009 | 781 | 392 | 5,869 |
| Share Capital | 2 | 3 | 4 | 4 | 11 |
Cash Flow
| Cash Flow | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 56 | 55 | -112 | 13 | 143 |
| Investing Activities | -207 | -692 | -68 | 511 | -201 |
| Operating Activities | -118 | -416 | -163 | -107 | -68 |
| Financing Activities | 381 | 1,162 | 118 | -391 | 412 |
Share Holding
| % Holding | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 37.77 % | 34.25 % | 29.79 % | 29.77 % |
| FIIs | 17.44 % | 18.54 % | 18.69 % | 19.39 % |
| DIIs | 12.56 % | 18.04 % | 18.10 % | 18.49 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 13.05 % | 12.50 % | 13.25 % | 12.42 % |
| Others | 19.18 % | 16.67 % | 20.17 % | 19.93 % |
| No of Share Holders | 98,425 | 82,712 | 87,760 | 87,416 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 14 Feb 2024 |  Change Of Name | NA | 14 Feb 2024 | 0.00 | 0.00 |
| 29 Jan 2025 |  Quarterly Result Announcement | NA | 29 Jan 2025 | 0.00 | 1,536.60 |
| 05 May 2025 | Quarterly Result Announcement | NA | 05 May 2025 | 1,593.85 | 1,593.00 |
| 04 Aug 2025 | Quarterly Result Announcement | NA | 04 Aug 2025 | 1,995.05 | 1,847.80 |
| 22 Sept 2025 |  Annual General Meeting | NA | 22 Sept 2025 | 1,855.40 | 1,836.20 |
| 11 Nov 2025 | Quarterly Result Announcement | NA | 11 Nov 2025 | 1,825.85 | 1,790.90 |
Announcements
Announcement under Regulation 30 (LODR)-Earnings Call Transcript10 days ago
10 days agoUpdate On Non-Participation Of The Representatives Of The Company In The Jefferies Conference10 days ago
10 days agoGeneral UpdatesNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 13, 2025
Nov 13, 2025Investor PresentationNov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 11, 2025
Nov 11, 2025 Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 11, 2025
Nov 11, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On 11/11/2025 To Approve The Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2025
Nov 05, 2025Board Meeting Intimation for Approving The Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 05, 2025
Nov 05, 2025Investor PresentationSep 26, 2025
Sep 26, 2025Announcement under Regulation 30 (LODR)-Scheme of ArrangementSep 26, 2025
Sep 26, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Voting Results Of The Annual General Meeting Held On 22Nd September 2025Sep 24, 2025
Sep 24, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 22, 2025
Sep 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 22, 2025
Sep 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 22, 2025
Sep 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 02, 2025
Sep 02, 2025Newspaper AdvertisementAug 30, 2025
Aug 30, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 29, 2025
Aug 29, 2025Notice Of The 18Th Annual General Meeting ("AGM") (1St AGM Post Listing) Of The Company Is Scheduled To Be Held On Monday September 22 2025 At 17:00 Hrs IST Through Video Conferencing / Other Audio-Visual Means.Aug 29, 2025
Aug 29, 2025Reg. 34 (1) Annual Report.Aug 29, 2025
Aug 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 06, 2025
Aug 06, 2025General UpdateAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 04, 2025
Aug 04, 2025General UpdatesAug 04, 2025
Aug 04, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 04, 2025
Aug 04, 2025Board Meeting Outcome for The Board Has Approved Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025Aug 04, 2025
Aug 04, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 31, 2025
Jul 31, 2025Board Meeting Intimation for Approval Of The Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025Jul 29, 2025
Jul 29, 2025General-UpdatesJul 15, 2025
Jul 15, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 07, 2025
Jul 07, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jul 07, 2025
Jul 07, 2025Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 01, 2025
Jul 01, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotJun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jun 27, 2025
Jun 27, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 23, 2025
Jun 23, 2025General-UpdatesJun 21, 2025
Jun 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Jun 18, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 16, 2025
Jun 16, 2025Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jun 16, 2025
Jun 16, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 13, 2025
Jun 13, 2025Mutual Fund Holdings
Quant Small Cap Fund Direct Plan-Growth 
Motilal Oswal Large and Midcap Fund Direct - Growth 
Mirae Asset Small Cap Fund Direct-Growth 
ITI Large & Mid Cap Fund Direct-Growth 
LIC MF Flexi Cap Fund Direct-Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
JM Focused Direct Plan-Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth 
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth 
SBI Nifty 500 Index Fund Direct-Growth 
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth 
Kotak Nifty Smallcap 250 Index Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 29.36
ATR(14)
Less Volatile 58.00
STOCH(9,6)
Oversold 8.03
STOCH RSI(14)
Oversold 16.95
MACD(12,26)
Bearish -14.95
ADX(14)
Weak Trend 13.67
UO(9)
Bearish 36.24
ROC(12)
Downtrend And Accelerating -9.00
WillR(14)
Oversold -96.72
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
